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Abstract  
Background:  
There is little clinical evidence to guide treatment decisions for ductal carcinoma in situ (DCIS) in older 
women. This study evaluated how the management of DCIS in women aged 70 or more compared 
with women aged 50-69 in England and Wales.  
Method: 
The study identified women aged ≥50 years with new unilateral DCIS diagnosed between 2014-2016 
from linked cancer registration and routine hospital datasets for England and Wales. Rates of surgery 
and adjuvant radiotherapy were examined by age, deprivation, fitness measures (comorbidity and 
frailty), method of presentation and tumour grade using multilevel logistic regression. 
Results:  
12,716 women were diagnosed with unilateral DCIS between 2014-2016, of whom 2,754 (22%) were 
aged ≥70 years and 74% were screen detected.  High grade DCIS was common, irrespective of age and 
method of presentation. Fewer women aged ≥70 had surgery compared to women aged 50–69 (81% 
vs. 94%), which was only partly explained by poor fitness. Use of radiotherapy following breast 
conserving surgery was strongly associated with grade, and was received by less than 16% of all 
patients with low grade tumours. Over 70% of women aged 50-69 with high grade DCIS received 
radiotherapy, but this fell to 35% among women aged ≥80. Use of radiotherapy was not associated 
with patient fitness. 
Conclusion:  
Treatment decisions for women with DCIS varied by age at diagnosis. Lower rates of surgery and 
adjuvant radiotherapy in older women were only partly explained by patient fitness. Better evidence 
is needed to aid treatment selection for older women with DCIS. 
 
Keywords: DCIS, breast cancer, geriatric oncology 
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1.0 Introduction1 
 
Ductal carcinoma in situ (DCIS) is typically diagnosed among women aged between 50 and 70 years, 
as a consequence of their participation in population-level breast screening programmes1, 2. DCIS 
accounts for around 6 – 9% of all breast cancers in women aged ≥70 years3, 4 and chronological age 
remains a significant risk factor1, 2. A diagnosis of DCIS increases the risk of developing invasive breast 
cancer5 but there is uncertainty concerning the natural history, rate of progression6 and long term 
survival outcomes7. It has been estimated that between 5-30% of all DCIS cases might progress to 
invasive breast cancer within 10 years6.  
 
The current recommended treatment for DCIS is surgical resection with or without radiotherapy8. 
Surgery for DCIS can be in the form of breast conserving surgery (BCS) or mastectomy, depending on 
the size of the tumour relative to the breast, presence of multi-centricity and patient preference. 
However, the effectiveness of treatments for different patient subgroups is under debate. It is 
suggested that surgery for low grade DCIS is unlikely to confer a survival benefit7. Additionally, 
although radiotherapy reduces the risk of recurrence, randomised trials have reported that it has no 
influence on breast cancer specific or overall survival9-11.  
 
Treatment decisions for older women can also be affected by the higher prevalence of comorbid 
conditions or frailty because both factors may reduce life expectancy12, 13. However, clinical guidelines 
do not provide advice on how treatments for DCIS should be tailored for these women14. The current 
non-stratified approach to the management of DCIS risks under or over-treatment, yet there is a lack 
of strong evidence to support omission of comprehensive treatment in the older population14. This 
study was undertaken to evaluate clinical patterns of care among women with DCIS in England and 
Wales, and to determine the extent to which increasing age and patient fitness affected the care 
received.  
 
                                                          
1 Abbreviations: BCS – breast conserving surgery, CCI – Charlson Comorbidity score, DCIS – ductal carcinoma in 
situ, eFI – electronic Frailty Index, HES – Hospital Episode Statistics, IMD – Index of multiple deprivation, Mx - 
mastectomy, NABCOP – National Audit of Breast Cancer in Older Patients, PEDW - Patient Episode Database for 
Wales, RTDS - Radiotherapy Dataset, OPCS - Office of Population Censuses and Surveys, SNB – sentinel node 
biopsy 
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2.0 Materials and methods 
 
2.1 Data sources 
The study was undertaken as part of the National Audit of Breast Cancer in Older Patients (NABCOP)15. 
NABCOP uses pseudonymised patient-level datasets provided by the National Cancer Registration and 
Analysis Service for England, and Wales Cancer Network for Wales.  The datasets included national 
cancer registrations, which provides data on patient demographics and tumour information, and 
extracts from the routine hospital admission databases for NHS hospitals (the English Hospital Episode 
Statistics (HES) and the Patient Episode Database for Wales (PEDW)). Use of radiotherapy was 
reported in the Radiotherapy Dataset (RTDS) for English patients and as part of the cancer registration 
dataset for Welsh patients. The methodology used to identify patients who received radiotherapy 
within the two datasets was equivalent.  
 
2.2 Study population and definitions 
Full details of the NABCOP cohort are detailed in the annual report15. For this analysis, the study cohort 
included all women aged 50 and over, diagnosed with a new unilateral DCIS (ICD-10 code: D05.1) from 
1 January 2014 to 31 December 2016 in NHS hospitals in England and Wales. Women with 
synchronous invasive breast cancers (defined as cancers diagnosed within six months of the DCIS 
diagnosis16) were not included (Appendix A). Each woman was allocated to an NHS trust (England) or 
local health board (Wales) based on their hospital of diagnosis. These are referred to as NHS 
organisations in this study.  
 
Information on patient demographics (age, deprivation), date of diagnosis, method of presentation 
and tumour characteristics were obtained from cancer registration datasets. Molecular markers such 
as hormone receptor status are not routinely collected for DCIS in many NHS organisations in the UK17.  
Area-level socioeconomic deprivation was measured using the Index of Multiple Deprivation (IMD), 
with the IMD values for the relevant geographical area in Wales18 and England19 converted to quintiles. 
Patient fitness was assessed using comorbidity and frailty measures. Comorbidity burden was 
measured using the Royal College of Surgeons of England Charlson Comorbidity Index (CCI) excluding 
malignancy20. This index was calculated based on the presence of specific medical problems, identified 
using ICD-10 diagnostic information in HES and PEDW in the two years prior to the date of cancer 
diagnosis21. The study also used a measure of frailty22, a distinct concept from comorbidity that 
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describes the dynamic and heterogeneous manifestation of age-related decline in physiological 
reserve and increased vulnerability to stressors23-25. Frailty was measured by adapting the electronic 
Frailty Index (eFI)26 for use within routine hospital databases. This involved mapping each of the 36 
eFI frailty deficits (excluding polypharmacy) to appropriate ICD-10 diagnosis codes and counting how 
many were recorded in HES and PEDW records in the two years prior to the date of diagnosis15.  
 
Primary surgery was defined by the first type of surgical procedure performed within six months of 
the date of diagnosis as recorded in HES or PEDW. Surgical procedures were described in the datasets 
using Office of Population Censuses and Surveys (OPCS) procedure codes, from which we 
distinguished between BCS (OPCS codes: B28.1, B28.2, B28.3, B28.5, B28.7, B28.8 and B28.9), 
mastectomy (any B27 code) with or without reconstruction (OPCS codes as per Mennie et al27), 
sentinel node biopsy (SNB)(T86.2, T87.3 and T91.1) and axillary node dissection (T85.2). Subsequent 
reoperations within six months of primary surgery were identified by the aforementioned mastectomy 
and BCS codes (with the inclusion of B28.4: re-excision of margins), with the same laterality code (Z94) 
as the primary surgery. Re-excision of margins was not limited to the specific OPCS code (B28.4) 
because it was inconsistently used across NHS organisations. Surgery performed within one week of 
the primary procedure was not considered to be a subsequent procedure because this was likely to 
have been performed for postoperative complications. Adjuvant radiotherapy was defined as the 
receipt of radiotherapy within six months of the last reoperation procedure.  
 
2.3 Statistical analysis  
Older women were defined as those aged ≥70 years to reflect the current national cut-off age of 70 
years for invitation to the NHS Breast Screening programme and Breast Test Wales. The differences 
between categorical variables were statistically assessed using chi-square tests.   
 
Multilevel logistic regression was used to investigate the relationships between the rates of breast 
surgery, SNB and adjuvant radiotherapy, respectively, and patient and tumour characteristics (level 
1), and to evaluate whether the treatment rates differed between NHS organisations (level 2). Patient 
factors included in the regression models were age, deprivation quintile, (nuclear) grade, method of 
tumour detection, CCI and eFI. Additionally, the model for radiotherapy included the number of 
reoperations and the model for SNB included the type of breast surgery performed. These models 
included a random intercept for each NHS organisation and evidence of between-organisation 
variation is described by the variance of the random intercepts. The c-statistic (a measure of 
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discrimination i.e. how well the model can distinguish between patients according to whether they 
experienced the outcome of interest or not) was used to assess how well the regression models fitted 
the data. Missing values were imputed using the multiple imputation by chained equations (MICE) 
method and model estimates produced from the 20 imputed datasets were combined using Rubin’s 
rules28. Missing data (grade, CCI and eFI) were assumed to be “missing at random”. Analysis for this 
study was conducted using Stata 15.1 (StataCorp LP, College Station, Texas USA). All statistical tests 
were two sided, and p values <0.05 were considered to be statistically significant. 
 
3.0 Results 
 
Between 1 January 2014 and 31 December 2016, 126,111 women aged ≥50 years in England and 
Wales were diagnosed with breast cancer. Among these, 12,716 women were diagnosed with 
unilateral DCIS – 11,807 (92.9%) in England and 909 (7.2%) in Wales. The median age was 63.5 years 
(range: 50 – 101) and 2,752 (21.6%) women were aged ≥70 years. Mammographic (screen) detection 
was the mode of presentation in 9,414 (74.0%) women, but the proportion varied among women of 
different ages. The clinical and pathological characteristics of the study cohort are summarised by age 
group and method of presentation in Table 1.  
 
3.1 Primary treatment for DCIS 
In total, 11,554 (90.9%) women had a surgical resection; this differed by age with fewer women aged 
≥70 having surgery compared to women aged 50–69 (80.5% vs. 93.7%). The observed rate of surgery 
decreased with increasing age (Figure 1) and among women with lower grade DCIS (Figure 2). BCS was 
the most common surgical procedure (79.0%). Among the remaining 21.0% of women having 
mastectomy, immediate breast reconstruction was rarely utilised among women aged ≥75 years 
(Table 1).  
 
Table 2 describes the proportion of women not receiving surgery in relation to patient and tumour 
characteristics. In addition to age and grade, the proportion of women who did not have surgery also 
varied by method of presentation and patient fitness. The associations between not having surgery 
and individual variables were attenuated after adjustment for potential confounding, but remained 
statistically significant. In particular, the adjusted odds ratios for the older age categories were much 
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closer to one, and only for women aged ≥ 80 years was the increased likelihood of not having surgery 
statistically significant.  
 
The multilevel regression model results showed that, after taking case mix into account, the rates of 
surgery differed between NHS organisations (Appendix B). The variation in the rate of surgery between 
NHS organisations was substantial among women aged ≥70 years, with the 10th and 90th centiles of 
the adjusted organisational rates being 74% and 90%, respectively.  In comparison, for the cohort of 
women aged 50–69 years, these rates were 94% and 98%, respectively (see Appendix B. for funnel 
plots).  
 
3.2 Axillary surgery in women having primary surgery for DCIS  
In the group of 11,540 women who received primary surgery, 3,597 (31.2%) also underwent axillary 
surgery; 97.7% of these axillary procedures were SNB. Over 85% of women who underwent 
mastectomy had a SNB (50–69 years: 88.8% vs. ≥70 years: 85.1%). Fewer women who received BCS 
had a SNB (50–69 years: 14.6% vs. ≥70 years: 17.3%). Overall, less than 0.5% of all women who had a 
SNB proceeded to have an axillary node dissection. There were found to be differences in the average 
adjusted rates of SNB across NHS organisations (Appendix B).  
 
3.3 Rate of radiotherapy within six months of primary BCS  
The proportion of women who had radiotherapy within six months of primary BCS was 55.6%. Women 
rarely received radiotherapy following mastectomy (2.5%). Women aged ≥70 years were less likely to 
undergo post-BCS radiotherapy compared to those aged 50 – 69 years (respectively, 43.1% vs. 58.4%). 
Over 70% of women aged 50-69 years with high grade tumours received radiotherapy, but this fell to 
35% among women aged ≥80 years (figure 3).  
 
Radiotherapy following BCS was received less commonly in older women, those with lower grade DCIS, 
screen detected presentation and those undergoing reoperations (Table 3). Deprivation and burden 
of comorbidity or frailty were not found to be associated with non-receipt of radiotherapy. Differences 
in the use of radiotherapy following BCS among the NHS organisations were more than expected from 
random variation alone (Appendix B). 
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4.0 Discussion 
 
Between 2014 and 2016, DCIS was diagnosed in over 4,000 women aged ≥50 years annually in England 
and Wales. One in five of these women were aged 70 and over. Despite the cessation of inclusion into 
national breast screening programmes, almost half of the women aged ≥70 years presented with DCIS 
through screening. This may be an effect of self-referral for mammographic screening or involvement 
in the AgeX trial on extending the NHS breast screening age to women over 70 in England29. 
 
Breast cancer clinicians have insufficient evidence on which to base decisions about the management 
of DCIS in older women. The principal treatment decision focuses on whether or not a woman has 
surgery. This study found that while most women are receiving surgery, these decisions appear to be 
influenced by several factors. In particular, lower rates of surgery were observed among women aged 
≥70 years. The effect of increased age on rate of surgery was mitigated when grade, comorbidity and 
frailty were taken into account but was still apparent among women aged 80 years or more.  
 
We observed that one in three women who had surgery also had an axillary procedure, despite the 
lack of evidence to support this practice 30. However, the majority of women who received SNB 
underwent mastectomy, which is in accordance with UK guidelines8 and is likely to reflect the 
proportion of women who were considered to be at high risk for invasive disease e.g. with a palpable 
mass. Among the women who underwent BCS, less than one in five received SNB.  
 
Fewer older women received adjuvant radiotherapy following BCS. However, this was not found to be 
related to burden of comorbidity or frailty, possibly because women in poorer physical health had not 
undergone surgery and consequently, were not candidates for radiotherapy. Additionally, older 
women who received surgery may have been offered but declined radiotherapy due to other factors 
(that could not be accounted for in this study). For example, the travel time to radiotherapy centres31 
may have deterred some older women from post-BCS radiotherapy.  
 
The results from multilevel regression models showed that there was significant variation across NHS 
organisations in their adjusted rates of surgery, SNB and adjuvant radiotherapy post-BCS.  This is 
perhaps to be expected given the limited evidence available to guide clinicians14. This study could not 
account for the influence of patient preferences on treatment decisions, but a study by Bleicher et al. 
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reported patient age to have minimal influence on DCIS treatment choices and level of involvement 
in decision making38. 
 
4.1 Strengths and Limitations 
The study has several strengths. Women were identified using the national cancer registries in England 
and Wales, reducing the risk of selection bias, and a focus on unilateral DCIS improved the 
homogeneity of the patient cohort. The use of national hospital datasets also ensures complete 
capture of all NHS hospital admissions for these patients reducing the risk of underreporting surgery 
rates.  Lastly, this study utilised measures of comorbidity and frailty which are known to influence the 
patterns of care for older women. Whilst there is no “gold-standard” measure of frailty, the study 
adapted the eFI frailty measure32 based on the concept of frailty being an accumulation of deficits33. 
The eFI was incorporated into general practitioner patient care records in 201734 and, although this 
adaptation requires further evaluation, the increasing prevalence of frailty in older women observed 
in this study is consistent with other studies32, 35.  
 
The study has some limitations. Routinely collected hospital data are subject to potential inaccuracies 
in coding and data entry, which could influence the estimated treatment rates. However, validation 
work has shown HES to be an accurate data source with 90-93% agreement with data provided by 
surgeons36. Additionally, the linkage of several datasets allowed a series of checks to be performed for 
consistency across shared data items, in order to minimise the effect of coding errors. The incomplete 
data on tumour size meant that this factor could not be taken into account during the analyses of 
primary surgery patterns and use of radiotherapy. However, it was reassuring to observe that, where 
recorded, the majority of tumour sizes were 2cm or less (irrespective of age) as would be expected 
from published evidence37. Moreover, the logistic regression models demonstrated a good fit with the 
data (c-statistics between 0.75-0.80) and so the absence of tumour size is unlikely to influence our 
conclusions about the impact of age on treatment patterns. Lastly, 1,162 women in this study did not 
have surgery and so the diagnosis of DCIS was not confirmed by the pathology results from the 
resected tissue. Mammographic lesions may harbour foci of invasive cancer in up to 20% of instances5, 
thus there is some uncertainty in the accuracy of the diagnosis among these patients. Nonetheless, 
this affects a small proportion of the overall cohort.   
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4.2 Comparison with other studies  
The finding that older age was an independent risk factor for not receiving primary surgery or 
radiotherapy for DCIS is consistent with published studies in both invasive38, 39 and non-invasive breast 
cancer4, 7. As the regression models demonstrated, age is only one of many factors that influence 
treatment decisions.  Indeed, the higher rate of surgery and radiotherapy in women with high grade 
DCIS compared to those with intermediate and low grade suggests a risk-stratified approach to 
managing DCIS in women aged ≥7040-42. However, the variation in the adjusted rate of surgery and 
radiotherapy in women aged ≥70 years between NHS organisations suggests local factors are 
contributing to different practices between organisations. A small number of women in this study will 
have been part of the randomised trial comparing surgery with active monitoring for low risk DCIS 
(LORIS)43. This is unlikely to have significant impact on the study findings as LORIS trial recruitment 
only commenced in July 2014 and 75% of women in this study do not meet the inclusion criteria of 
having low or intermediate, screen-detected DCIS. Nonetheless, the results of LORIS and other similar 
ongoing trials44, 45 will provide important contributions to the evidence base on the effectiveness of 
treatments for women with DCIS, and the enrolment of eligible patients into these trials is 
encouraged.   
 
In older women, the risk of mortality due to poor fitness can outweigh the benefit of comprehensively 
treating DCIS, but there is an absence of studies which report on survival using patient fitness 
measures7, 14. Health professionals can be inconsistent in their estimation of life expectancy in older 
frail women46. Furthermore, it is estimated that fewer than 30% of cases progress to an invasive cancer 
within 10 years6. Further research is therefore essential to determine how patient fitness affects 
treatment decisions and survival after a diagnosis of DCIS.  
 
5.0 Conclusion  
In conclusion, between 2014 and 2016, 12,716 women aged 50 and over presented with DCIS in 
England and Wales. One in five of these women were aged 70 and over, despite the cessation of 
invitations to the NHS breast screening programme at age 70. Treatment decisions for women with 
DCIS vary by age at diagnosis, with older women having lower rates of surgery and adjuvant 
radiotherapy. The differences in treatment decisions across age groups is only partly explained by 
patient fitness. There is a need for in depth review of age-based clinical decision making and better 
evidence to aid treatment selection for older women with DCIS. 
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Figure 1: Type of surgical treatment recorded in women diagnosed with DCIS in NHS 
organisations in England and Wales, by age group at diagnosis. 
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Figure 2: Proportion of women recorded to have received primary surgery for DCIS in NHS 
organisations in England and Wales, by age group at diagnosis and DCIS grade. 
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Figure 3: Proportion of women recorded to have received adjuvant radiotherapy following 
breast conserving surgery for DCIS in NHS organisations in England and Wales, by age group 
at diagnosis and DCIS grade.  
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Table 1: Baseline clinical and pathological characteristics, and type of recorded treatment for 
unilateral DCIS in women diagnosed in NHS Hospitals in England and Wales between January 
2014 and December 2016, by screen detected status.  
 (* Note: p-values from analysis of the overall group) 
 Screen detected   
 Yes No Total P-value 
(group) 
 50-69 
years 
≥70 years 50-69 
years 
≥70 years   
Total number of women 8134 (86%) 1280 (14%) 1828 (55%) 1474 (45%) 12716  
Non-invasive grade 
High 5042 (65%) 727 (61%) 914 (56%) 574 (47%) 7257 <0.001 
Intermediate 2019 (26%) 355 (30%) 492 (30%) 462 (38%) 3328  
Low  637 (8%) 119 (10%) 236 (14%) 196 (16%) 1188  
Unknown 436 79 186 242 943  
Tumour size (cm) 
0 - ≤ 1 1135 (50%) 180 (51%) 176 (41%) 141 (42%) 1632 <0.001 
             > 1 - ≤ 2 847 (38%) 124 (35%) 175 (41%) 141 (42%) 1287  
2 +  273 (12%) 52 (15%) 78 (18%) 50 (15%) 616  
Unknown 5879 924 1399 1142 9344  
Charlson Comorbidity Index (CCI) 
0 7125 (91%) 1064 (85%) 1447 (85%) 966 (71%) 10602 <0.001 
             1 577 (7%) 143 (11%) 191 (11%) 248 (18%) 1159  
2 + 137 (2%) 39 (3%) 62 (4%) 149 (11%) 387  
Unknown 295 34 128 111 568  
       
Number of frailty deficiencies (eFI) 
             0 6452 (82%) 843 (68%) 1208 (71%) 660 (48%) 9163 <0.001 
             1 717 (9%) 168 (13%) 232 (14%) 170 (12%) 1287  
2 367 (5%) 131 (11%) 142 (8%) 180 (13%) 820  
3 + 303 (4%) 104 (8%) 118 (7%) 353 (26%) 878  
Unknown 295 34 128 111 568  
IMD quintile 
1 - most deprived 1080 (13%) 268 (15%) 136 (11%) 216 (15%) 1700 0.005 
             2 1383 (17%) 321 (18%) 204 (16%) 265 (18%) 2173  
3 1646 (20%) 387 (21%) 260 (20%) 317 (22%) 2610  
4 1952 (24%) 404 (22%) 326 (25%) 326 (22%) 3008  
5 – least deprived 2073 (25%) 448 (25%) 354 (28%) 350 (24%) 3225  
Type of treatment 
No surgery 255 (14%) 445 (30%) 373 (5%) 89 (7%) 1162 <0.001 
BCS 1134 (62%) 722 (49%) 6312 (78%) 962 (75%) 9130  
Simple mastectomy 226 (12%) 282 (19%) 686 (8%) 177 (14%) 1371  
Mx + reconstruction 213 (12%) 25 (2%) 763 (9%) 52 (4%) 1053  
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Table 2: Proportion of women recorded to have no surgery for DCIS in NHS organisations in 
England and Wales between January 2014 and December 2016.  
 Total 
number of 
women 
Proportion 
receiving no 
surgery 
Unadjusted 
OR 
Adjusted 
OR 
95% confidence 
interval 
P-value 
Age at diagnosis (years) 
50 - 54  2798 7% 1 1  < 0.001 
55 - 59 2248 7% 0.99 1.07 0.85 to 1.36  
60 - 64 2241 6% 0.96 0.98 0.78 to 1.25  
65 - 69 2675 6% 0.84 0.78 0.61 to 0.98  
70 - 74 1399 9% 1.32 1.00 0.77 to 1.29  
75 - 79 632 16% 2.91 1.32 0.99 to 1.77  
80 - 84 365 43% 5.10 1.98 1.43 to 2.74  
85 +  358 61% 24.03 8.81 6.49 to 11.97  
Non-invasive grade 
High 7750 6% 1 1  < 0.001 
Intermediate 3646 11% 2.06 1.74 1.47 to 2.05  
Low 1320 21% 4.24 3.64 2.99 to 4.44  
Screen detected status 
Yes 9414 7% 1 1  < 0.001 
No 3302 18% 5.36 2.73 2.34 to 3.2  
Charlson comorbidity Index 
0 11072 6% 1 1  0.003 
1 1226 11% 2.87 1.36 1.01 to 1.83  
2+ 418 17% 5.96 1.99 1.35 to 2.94  
Frailty deficiencies 
0 9551 6% 1 1  0.001 
1 1351 11% 1.72 1.25 0.96 to 1.62  
2 874 17% 2.90 1.53 1.12 to 2.08  
3+ 940 30% 6.32 2.11 1.47 to 3.02  
IMD quintile 
1 - most deprived 1700 11% 1 1  0.193 
2 2173 9% 0.72 0.79 0.62 to 1.01  
3 2610 10% 0.82 0.95 0.76 to 1.20  
4 3008 8% 0.70 0.85 0.67 to 1.07  
5 – least deprived 3225 9% 0.79 0.98 0.78 to 1.24  
 
 
 
 
 
20 
 
Table 3: Proportion of women recorded to have no radiotherapy following breast conserving 
surgery for DCIS in NHS organisations England and Wales between January 2014 and 
December 2016. 
 Total number 
of women 
Proportion 
receiving no 
radiotherapy 
Unadjusted 
OR 
Adjusted 
OR 
95% confidence 
interval 
P-value 
Age at diagnosis (years) 
50 - 54  1984 44% 0 1  <0.001 
55 - 59 1643 38% 0.78 0.89 0.76 to 1.04  
60 - 64 1699 40% 0.80 0.99 0.85 to 1.16  
65 - 69 2063 43% 0.83 1.04 0.90 to 1.21  
70 - 74 997 51% 1.21 1.35 1.12 to 1.62  
75 - 79 392 58% 1.96 1.40 1.07 to 1.85  
80+ 274 76% 6.63 3.81 2.69 to 5.39  
Non-invasive grade 
High 5403 27% 1 1  < 0.001 
Intermediate 2713 66% 3.20 6.19 5.52 to 6.94  
Low 907 85% 9.51 19.67 15.77 to 24.55  
Screen detected status 
Yes 7220 41% 1 1  < 0.001 
No 1832 57% 2.81 1.49 1.29 to 1.71  
Charlson comorbidity Index  
0 8072 43% 1 1  0.21 
1 773 52% 1.61 1.16 0.91 to 1.47  
2+ 204 50% 2.14 0.84 0.54 to 1.31  
No. of frailty deficiencies 
0 7033 42% 1 1  0.263 
1 960 50% 1.32 1.16 0.97 to 1.39  
2 563 50% 1.53 1.00 0.78 to 1.29  
3+ 493 54% 2.26 1.24 0.89 to 1.71  
Number of reoperations 
0 6546 43% 1 1  < 0.001 
1 2101 43% 0.45 1.14 1.01 to 1.28  
2+ 405 72% 1.60 7.07 5.47 to 9.14  
IMD quintile       
1 - most deprived 1157 47% 1 1  0.525 
2 1551 41% 0.76 0.86 0.71 to 1.04  
3 1837 44% 0.87 0.98 0.81 to 1.18  
4 2178 44% 0.83 0.94 0.79 to 1.13  
5 – least deprived 2329 45% 0.84 0.93 0.78 to 1.12  
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Appendix A 
A flow diagram on the processes of defining the study population from the datasets provided by 
English and Welsh cancer registries  
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Appendix B: Statistical results related to variation between NHS organisations 
 
Multilevel logistic regression were fitted to account for the clustering of women treated within NHS 
organisations; such models enabled evaluation of the variance of treatment rates at NHS 
organisation level. Between organisation variation is described by the variance of the random 
intercepts, with evidence for there being significant differences between NHS organisations if the 
95% confidence interval for the variance does not include 0.   
 
All the regression models used to analyse the relationship between the rates of surgery, SNB (in all 
surgery) and radiotherapy following BCS, and patient factors; found evidence of differences between 
NHS organisations in England and Wales. This is demonstrated by the estimated variances of the 
random intercepts shown in the table below.   
 
 Variance of random intercept 
(95% confidence interval) 
c-statistic 
Primary surgery for DCIS 0.16 (0.09 to 0.30) 0.80 
SNB in women having surgery for DCIS 
 
0.36 (0.28 to 0.46) 0.76 
Post-BCS radiotherapy 
 
0.68 (0.50 to 0.80) 0.79 
 
The table also contains the values of the c-statistic, a measure of the ability of the model to 
discriminate between women who did and did not have the outcome of interest. All of the multilevel 
logistic regression models demonstrated a good fit with the data. 
 
Funnel plots describing the variation in the adjusted rates of primary surgery for DCIS between NHS 
organisations in England and Wales are shown below.   
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Risk adjusted rates for surgical treatment of DCIS in women aged 50 – 69 years in NHS organisations 
in England and Wales between 2014 and 2016. 
 
 
Risk adjusted rates for surgical treatment of DCIS in women aged ≥70 years in NHS organisations in 
England and Wales between 2014 and 2016.  
 
 
 
